摘要:
The present invention relates to a novel crystalline form of 4- (5-{ (IR) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy } -4- methyl-4H-l, 2, 4-triazol-3-yl) pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it.
摘要:
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β 2 -adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
摘要:
The present invention relates to compounds of Formula (I) wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
摘要:
The present invention relates to a novel benzenedicarboxamide derivative and the use thereof as an insecticide having the formula (I) wherein the chemical groups W 1 to W 9 , and R 1 to R 3 are as defined herein.
摘要:
The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.
摘要:
The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, 1 processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
摘要:
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR 3 and (Ar 1 ) 2 CR 4 is optionally substituted benzhydryl.
摘要翻译:公开了有效改善由不需要的钙通道活性,特别是不需要的N型或T型钙通道活性表征的病症的方法和化合物。 具体地说,通式(1)中公开了一系列含异唑的化合物,其中Z是N或CHNR 3,和(Ar 1)2 SUB > CR 4是任选取代的二苯甲基。
摘要:
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SlP receptors.
摘要:
The present invention is concerned with aryl-4-ethynyl-isoxazole derivatives of formula (I) wherein R 1 to R 5 are as described in the specification, R 5 representing an optionally substituted aryl or heteroaryl. It has been found that this class of compounds show high affinity and selectivity for GABA A α5 receptor binding sites, being useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译:本发明涉及式(I)的芳基-4-乙炔基 - 异恶唑衍生物,其中R 1至R 5如说明书中所述,R“ 5表示任选取代的芳基或杂芳基。 已经发现,这类化合物对GABA A a5受体结合位点具有高亲和力和选择性,可用作认知增强剂或用于治疗认知障碍如阿尔茨海默病。
摘要:
The invention relates to sulfonamide compounds of formula (I), where A, B, R 3 and R 4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types of sleep disorders, all kinds of cognitive dysfunctions in the healthy population and psychiatric and neurologic disorders. Formula (I).